JP5662684B2 - 甲状腺障害リスクの同定方法 - Google Patents

甲状腺障害リスクの同定方法 Download PDF

Info

Publication number
JP5662684B2
JP5662684B2 JP2009549628A JP2009549628A JP5662684B2 JP 5662684 B2 JP5662684 B2 JP 5662684B2 JP 2009549628 A JP2009549628 A JP 2009549628A JP 2009549628 A JP2009549628 A JP 2009549628A JP 5662684 B2 JP5662684 B2 JP 5662684B2
Authority
JP
Japan
Prior art keywords
thyroid
treatment
patients
antibody
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009549628A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010519512A5 (https=
JP2010519512A (ja
Inventor
マーゴリン，デビッド，エイチ．
Original Assignee
ジェンザイム コーポレーション
ジェンザイム コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェンザイム コーポレーション, ジェンザイム コーポレーション filed Critical ジェンザイム コーポレーション
Publication of JP2010519512A publication Critical patent/JP2010519512A/ja
Publication of JP2010519512A5 publication Critical patent/JP2010519512A5/ja
Application granted granted Critical
Publication of JP5662684B2 publication Critical patent/JP5662684B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/635—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70592—CD52
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/046—Thyroid disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2009549628A 2007-02-16 2008-02-15 甲状腺障害リスクの同定方法 Active JP5662684B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90173207P 2007-02-16 2007-02-16
US60/901,732 2007-02-16
PCT/US2008/002047 WO2008103292A1 (en) 2007-02-16 2008-02-15 Method of identifying risk for thyroid disorder

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014110361A Division JP6058585B2 (ja) 2007-02-16 2014-05-28 甲状腺障害リスクの同定方法

Publications (3)

Publication Number Publication Date
JP2010519512A JP2010519512A (ja) 2010-06-03
JP2010519512A5 JP2010519512A5 (https=) 2011-03-17
JP5662684B2 true JP5662684B2 (ja) 2015-02-04

Family

ID=39434244

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009549628A Active JP5662684B2 (ja) 2007-02-16 2008-02-15 甲状腺障害リスクの同定方法
JP2014110361A Active JP6058585B2 (ja) 2007-02-16 2014-05-28 甲状腺障害リスクの同定方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014110361A Active JP6058585B2 (ja) 2007-02-16 2014-05-28 甲状腺障害リスクの同定方法

Country Status (21)

Country Link
US (3) US20100136587A1 (https=)
EP (2) EP2538217A1 (https=)
JP (2) JP5662684B2 (https=)
CN (2) CN101657721B (https=)
AU (1) AU2008219097B2 (https=)
BR (1) BRPI0807601B8 (https=)
CA (1) CA2678199A1 (https=)
CY (1) CY1118663T1 (https=)
DK (1) DK2130044T3 (https=)
ES (1) ES2612558T3 (https=)
HR (1) HRP20170121T1 (https=)
HU (1) HUE031421T2 (https=)
IL (2) IL200314A (https=)
LT (1) LT2130044T (https=)
MX (1) MX2009008642A (https=)
PL (1) PL2130044T3 (https=)
PT (1) PT2130044T (https=)
RS (1) RS55636B1 (https=)
RU (1) RU2013120485A (https=)
SI (1) SI2130044T1 (https=)
WO (1) WO2008103292A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9498528B2 (en) * 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
FR2934129B1 (fr) * 2008-07-24 2014-05-02 Oreal Procede de traitement cosmetique.
EP2335066B1 (en) * 2008-09-19 2016-12-28 University of Utah Research Foundation Methods for prediction of multiple sclerosis disease and therapy response
CN106257288A (zh) * 2016-08-15 2016-12-28 余洋 一种血清TPOAb IgG4水平检测方法
CN112312921A (zh) 2018-07-02 2021-02-02 美国西门子医学诊断股份有限公司 新型甲状腺过氧化物酶自身抗体免疫测定
KR102469743B1 (ko) 2020-06-10 2022-11-22 주식회사 타이로스코프 약물 복용에 따른 갑상선 기능 모니터링 방법, 이를 수행하는 모니터링 서버 및 사용자 단말
EP4001919A1 (en) * 2020-11-13 2022-05-25 Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal Predictive biomarkers of autoimmunity in patients treated with alemtuzumab
WO2024158259A1 (ko) * 2023-01-27 2024-08-02 주식회사 타이로스코프 대상에 대한 갑상선기능이상증의 예측방법 및 시스템

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
GB2265713A (en) * 1992-05-16 1993-10-06 R S R Limited Assay for autoantibodies against thyroglobulin or thyroid peroxidase
DE19710211C2 (de) * 1997-03-12 1999-12-16 Brahms Diagnostica Gmbh Verfahren zur Bestimmung von Schilddrüsen-Autoantikörpern
GB9823397D0 (en) * 1998-10-27 1998-12-23 Rsr Ltd Assays for thyroid autoantibodies
JP2008523785A (ja) * 2004-10-12 2008-07-10 カーランテック，インコーポレーテッド 神経変性、自己免疫脱髄、および糖尿病のウイルス病原に対する動物モデル系
US9498528B2 (en) 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)

Also Published As

Publication number Publication date
JP2014149313A (ja) 2014-08-21
RU2013120485A (ru) 2014-11-20
BRPI0807601A2 (pt) 2014-05-06
MX2009008642A (es) 2009-10-20
LT2130044T (lt) 2017-02-10
CN101657721A (zh) 2010-02-24
AU2008219097B2 (en) 2011-06-23
CY1118663T1 (el) 2017-07-12
CN108303546B (zh) 2023-01-03
SI2130044T1 (sl) 2017-03-31
IL242391A (en) 2017-09-28
IL200314A0 (en) 2010-04-29
US9664688B2 (en) 2017-05-30
PL2130044T3 (pl) 2017-04-28
US20130095507A1 (en) 2013-04-18
EP2130044A1 (en) 2009-12-09
EP2130044B1 (en) 2016-10-26
RS55636B1 (sr) 2017-06-30
CN108303546A (zh) 2018-07-20
US20100136587A1 (en) 2010-06-03
BRPI0807601B1 (pt) 2021-02-23
HK1257419A1 (zh) 2019-10-18
US20170307629A1 (en) 2017-10-26
DK2130044T3 (en) 2017-02-06
BRPI0807601B8 (pt) 2021-07-27
JP2010519512A (ja) 2010-06-03
ES2612558T3 (es) 2017-05-17
HRP20170121T1 (hr) 2017-03-24
IL200314A (en) 2015-11-30
WO2008103292A1 (en) 2008-08-28
CA2678199A1 (en) 2008-08-28
US10648986B2 (en) 2020-05-12
AU2008219097A1 (en) 2008-08-28
EP2538217A1 (en) 2012-12-26
JP6058585B2 (ja) 2017-01-11
HUE031421T2 (hu) 2017-07-28
RU2009134313A (ru) 2011-03-27
CN101657721B (zh) 2018-02-23
PT2130044T (pt) 2017-02-03

Similar Documents

Publication Publication Date Title
JP6058585B2 (ja) 甲状腺障害リスクの同定方法
Kadlubowski et al. The lack of specificity of ophthalmic immunoglobulins in Graves’ disease
EP1181554B1 (en) Method for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses
RU2707755C2 (ru) Способ прогнозирования риска возникновения рака или диагностирования рака у женщины
Attar et al. The CD63 basophil activation test as a diagnostic tool for assessing autoimmunity in patients with chronic spontaneous urticaria
US20180094317A1 (en) Diagnostics for pulmonary arterial hypertension and sudden cardiac death
EP4176267B1 (en) Amh and/or inhibin b as a biomarker for an effect of a treatment to improve male fertility
JP2016508607A (ja) リウマチ性関節炎の診断方法
RU2575560C2 (ru) Способ выявления риска расстройства щитовидной железы
HK1180393A (en) Method of identifying risk for thyroid disorder
HK1257419B (en) Method of identifying risk for thyroid disorder
EP2123677A1 (en) Anti-brak (cxcl14) human monoclonal antibody and use thereof
Gauna et al. Immunological aspects of Graves’ disease patients in different clinical stages
US20140322211A1 (en) Tenascin-c and use thereof in rheumatoid arthritis
US20200124612A1 (en) Detection of predictors of preeclampsia
US11674951B2 (en) Methods for identifying a treatment for rheumatoid arthritis
Kadhim et al. Therapeutic drug monitoring of adalimumab for dose optimization during maintenance therapy in patients with ulcerative colitis: real-world data
Condon Improving Outcomes in Glomerulonephritis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110126

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120510

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130604

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130611

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130702

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140528

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141205

R150 Certificate of patent or registration of utility model

Ref document number: 5662684

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250